Contact
searchSearch
HMP Global
Login

Ovarian Cancer

Ovarian Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Rebecca Porter, MD, PhD
Videos
Biomarker-Targeted Therapies Expand Treatment Selection Beyond Platinum Sensitivity in Recurrent Ovarian Cancer
10/30/2026
Rebecca Porter, MD, PhD
Rebecca Porter, MD, discusses evolving treatment strategies for recurrent ovarian cancer, highlighting the expanding role of antibody-drug conjugates, FRα and HER2-biomarker testing, and the importance of integrating molecular...
Rebecca Porter, MD, discusses evolving treatment strategies for recurrent ovarian cancer, highlighting the expanding role of antibody-drug conjugates, FRα and HER2-biomarker testing, and the importance of integrating molecular...
Rebecca Porter, MD, discusses...
10/30/2026
Oncology
Vanda Salutari, MD, Policlinico Gemelli
Videos
BEHOLD-1: Updated Results With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
10/29/2026
Vanda Salutari, MD
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...
Vanda Salutari, MD, discusses...
10/29/2026
Oncology
Lucy Gilbert, MD, MSc
Videos
Relacorilant Plus Nab-paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Regardless of Prior Taxane Use
06/23/2026
Lucy Gilbert, MD, MSc
Lucy Gilbert, MD, MSc, Chair of Oncology at McGill University and Chief of Gynecological Oncology at the McGill University Health Centre, discusses findings from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel versus...
Lucy Gilbert, MD, MSc, Chair of Oncology at McGill University and Chief of Gynecological Oncology at the McGill University Health Centre, discusses findings from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel versus...
Lucy Gilbert, MD, MSc, Chair of...
06/23/2026
Oncology
Cara Mathews, MD
Videos
Rinatabart Sesutecan Plus Bevacizumab in Recurrent Ovarian Cancer
05/21/2026
Cara Mathews, MD
Cara Mathews, MD, discusses results from the cohort D2 of the phase 1/2 RAINFOL-01 study assessing rinatabart sesutecan plus bevacizumab in patients with recurrent ovarian cancer.
Cara Mathews, MD, discusses results from the cohort D2 of the phase 1/2 RAINFOL-01 study assessing rinatabart sesutecan plus bevacizumab in patients with recurrent ovarian cancer.
Cara Mathews, MD, discusses...
05/21/2026
Oncology
Alexander Olawaiye, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
05/07/2026
Alexander Olawaiye, MD
Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Alexander Olawaiye, MD, discusses final overall survival results from the phase 3 ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Alexander Olawaiye, MD,...
05/07/2026
Oncology
Alison Schram, MD
Videos
Rezatapopt Shows Clinical Promise in TP53-Mutated Ovarian Cancer
05/04/2026
Alison Schram, MD
Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.
Alison Schram, MD, discusses results from the phase 2 PYNNACLE trial which assessed rezatapopt in TP53 Y220C mutated advanced or metastatic ovarian cancer.
Alison Schram, MD, discusses...
05/04/2026
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel for Patients With Platinum-Resistant Ovarian Cancer
04/30/2026
Brian Slomovitz, MD
Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses results from the ROSELA trial which led to the recent FDA approval of relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
04/30/2026
Oncology
Emese Zsiros, MD, PhD
Videos
Pembrolizumab Plus Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer
04/24/2026
Emese Zsiros, MD, PhD
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses results from the phase 3 KEYNOTE-B96 trial, which demonstrated that pembrolizumab improves survival while maintaining quality of life in patients with platinum-resistant ovarian cancer.
Emese Zsiros, MD, PhD, discusses...
04/24/2026
Oncology
Rebecca Porter, MD, PhD
Videos
Rethinking Treatment Strategies in Recurrent Ovarian Cancer
03/17/2026
Rebecca Porter, MD, PhD
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD, discusses whether treatment paradigms for recurrent ovarian cancer should evolve beyond traditional regulatory standards.
Rebecca Porter, MD, PhD,...
03/17/2026
Oncology
Toon Van Gorp, MD, PhD, University Hospital Leuven
Videos
Mirvetuximab Soravtansine Confirmed Standard of Care for Folate Receptor Alpha-Positive, Platinum-Resistant Ovarian Cancer
03/17/2025
Toon Van Gorp, MD, PhD
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on...
03/17/2025
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use